An interventional study of Therapy services (ACQUIREc Therapy) in Hemiparetic Cerebral Palsy, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2009-10-08.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
A multisite trial to testing different dosage levels of a systematic form of Pediatric Constraint-Induced (CI) Therapy called ACQUIREc Therapy. The high dosage treatment involved 6 hours of daily therapy services for 21 days. This was compared to a moderate dosage level of 3 hours of daily therapy services for 21 days. It was hypothesized that children receiving the higher therapy dosage would have greater and more clinically significant benefits from ACQUIREc Therapy but that both groups of children would benefit from the therapy services.
1,853 studies on the registry are indexed under Cerebral Palsy; 435 are open to participants now.
This study's enrollment of 18 is below the median of 33 across 1,368 interventional studies indexed under Cerebral Palsy.
Browse Cerebral Palsy studies →University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.
Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Therapy services (ACQUIREc Therapy)
Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
Also known as: Occupational Therapy, Physical Therapy, Pediatric CI Therapy, ACQUIREc Therapy
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham